Schleifer Leonard S's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Jun 13, 2024
- Accession no.
- 0001104659-24-071247
- Filed
- Jun 13, 2024
- Trade date
- Jun 11-12, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $25.6M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schleifer Leonard SCIK 0001218629 | Director, Officer (Bd. Co-Chair, President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 11, 2024 | Common Stock | SSaleDisposed | −7,321 | $1,015.28F2 | −$7,432,864.88 | 56,877 | Indirect | |
| Jun 11, 2024 | Common Stock | SSaleDisposed | −1,743 | $1,016.04F3 | −$1,770,957.72 | 55,134 | Indirect | |
| Jun 12, 2024 | Common Stock | SSaleDisposed | −14,879 | $1,015.30F4 | −$15,106,648.7 | 40,255 | Indirect | |
| Jun 12, 2024 | Common Stock | SSaleDisposed | −270 | $1,016.62F5 | −$274,487.4 | 39,985 | Indirect | |
| Jun 12, 2024 | Common Stock | CConversionAcquired | +1,000 | $0.00 | $0 | 1,000 | Indirect | |
| Jun 12, 2024 | Common Stock | SSaleDisposed | −1,000 | $1,025.27F6 | −$1,025,270 | 0 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2024 | Common Stock | CConversionDisposed | −1,000 | $0.00 | $0 | 14,775 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents volume-weighted average price of sales of 7,321 shares of common stock of Regeneron Pharmaceuticals, Inc. (the "Company") on June 11, 2024 at prices ranging from $1,015.00 to $1,015.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 11, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Represents volume-weighted average price of sales of 1,743 shares of Company stock on June 11, 2024 at prices ranging from $1,016.04 to $1,016.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 11, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
Represents volume-weighted average price of sales of 14,879 shares of Company stock on June 12, 2024 at prices ranging from $1,015.00 to $1,015.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
Represents volume-weighted average price of sales of 270 shares of Company stock on June 12, 2024 at prices ranging from $1,016.10 to $1,016.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F6
Represents volume-weighted average price of sales of 1,000 shares of Company stock on June 12, 2024 at prices ranging from $1,025.00 to $1,025.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price.
Referenced by the price of 1 transaction in Table I.